Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease: Effect of Baseline Amikacin and Clarithromycin Susceptibility on Culture Conversion

被引：0
|
作者：
Winthrop, K. L. [1 ]
Flume, P. A. [2 ,3 ]
Thomson, R. [4 ]
Brown-Elliott, B. A. [5 ]
Wallace, R. J., Jr. [5 ]
Griffith, D. E. [6 ]
Pennings, L. J. [7 ]
Coulter, C. [8 ]
Syrmis, M. [8 ]
Pandey, S. [8 ]
Yuen, D. [9 ]
Mange, K. [9 ]
van Ingen, J. [7 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA
[2] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA
[3] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA
[4] Univ Queensland, Gallipoli Med Res Inst, Brisbane, Qld, Australia
[5] Univ Texas Hlth Sci Ctr Tyler, Mycobacteria Nocardia Lab, Tyler, TX USA
[6] Univ Texas Hlth Sci Ctr Tyler, Tyler, TX USA
[7] Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands
[8] Pathol Queensland, Queensland Mycobacterium Reference Lab, Brisbane, Qld, Australia
[9] Insmed Inc, Bridgewater, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4494
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease
    Kim, Bo-Guen
    Kim, Sae Rom
    Jhun, Byung Woo
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (02) : 202 - 205
  • [22] Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
    Winthrop, K. L.
    Eagle, G.
    Thomson, R. M.
    Aksamit, T. R.
    Hasegawa, N.
    Morimoto, K.
    Addrizzo-Harris, D. J.
    O'Donnell, A. E.
    Marras, T. K.
    Flume, P. A.
    Loebinger, M. R.
    Morgan, L. C.
    Codecasa, L. R.
    Hill, A. T.
    Ruoss, S. J.
    Yim, J. J.
    Ringshausen, F. C.
    Field, S. K.
    Nezamis, J.
    Griffith, D. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [23] Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease
    Yanagihara, Toyoshi
    Ogata, Hiroaki
    Mori, Asami
    Kadowaki, Masako
    Moriuchi, Yuki
    Ishimatsu, Akiko
    Otsuka, Junji
    Taguchi, Kazuhito
    Moriwaki, Atushi
    Yoshida, Makoto
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [24] AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) ADDED TO COMBINATION REGIMEN ON RECURRENCE IN NEWLY DIAGNOSED OR RECURRENT MYCOBACTERIUM AVIUM COMPLEX (MAC): THE ARISE STUDY
    van Ingen, Jakko
    Terschlusen, Eva
    Yuen, Dayton
    May, Daniel
    Nevoret, Marie-Laure
    Ciesielska, Monika
    Stein, Daniel
    Mange, Kevin
    CHEST, 2024, 166 (04) : 995A - 996A
  • [25] THE RELATIONSHIP BETWEEN CULTURE CONVERSION AND IMPROVEMENT IN 6-MINUTE WALK TEST DISTANCE IN THE CONVERT STUDY EVALUATING AMIKACIN LIPOSOME INHALATION SUSPENSION FOR REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
    Mange, Kevin
    Roberts, Kevin
    Zandvliet, Anthe
    Witjes, Han
    Neve, Marta
    Lovern, Mark
    CHEST, 2019, 156 (04) : 1126A - 1126A
  • [26] Acquisition of Amikacin Resistance during Amikacin Liposome Inhalation Suspension Add-on Therapy for Mycobacterium avium Complex Pulmonary Disease
    Sano, Hirohito
    Fujino, Naoya
    Numakura, Tadahisa
    Yamada, Mitsuhiro
    Tode, Naoki
    Sugiura, Hisatoshi
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (03) : 526 - 529
  • [27] Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
    Urabe, Naohisa
    Sakamoto, Susumu
    Tokita, Nozomi
    Yoshida, Hiromichi
    Usui, Yusuke
    Shimizu, Hiroshige
    Sekiya, Muneyuki
    Miyoshi, Shion
    Nakamura, Yasuhiko
    Isobe, Kazutoshi
    Kishi, Kazuma
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [28] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
    Christopher M. Rubino
    Nikolas J. Onufrak
    Jakko van Ingen
    David E. Griffith
    Sujata M. Bhavnani
    Dayton W. Yuen
    Kevin C. Mange
    Kevin L. Winthrop
    European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 277 - 287
  • [29] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
    Rubino, Christopher M.
    Onufrak, Nikolas J.
    van Ingen, Jakko
    Griffith, David E.
    Bhavnani, Sujata M.
    Yuen, Dayton W.
    Mange, Kevin C.
    Winthrop, Kevin L.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (02) : 277 - 287
  • [30] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease (vol 79, pg 555, 2019)
    Shirley, Matt
    DRUGS, 2019, 79 (07) : 791 - 791
12345